Skip to main content
Top
Published in: Inflammation 1/2016

01-02-2016

Quercetin Protects Mice from ConA-Induced Hepatitis by Inhibiting HMGB1-TLR Expression and Down-Regulating the Nuclear Factor Kappa B Pathway

Authors: Xi Li, Hong-chun Liu, Qun-yan Yao, Bei-li Xu, Shun-cai Zhang, Chuan-tao Tu

Published in: Inflammation | Issue 1/2016

Login to get access

Abstract

The dietary flavonoid quercetin has hepatoprotective effects. We analyzed the effects of quercetin on concanavalin A (ConA)-induced hepatitis in mice and its underlying molecular mechanisms of action. Mice were administered quercetin (50 mg/kg body weight, i.p.) or vehicle 30 min before intravenous administration of ConA. Quercetin pretreatment significantly reduced the ConA-induced elevations in plasma aminotransferase concentrations and liver necrosis, as well as reducing serum concentrations of the pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interferon-γ, and interleukin-4. Quercetin pretreatment also reduced expression of high-mobility group box 1 protein (HMGB1) and toll-like receptor (TLR)-2 and TLR-4 messenger RNA (mRNA) and protein in liver tissues. Quercetin pretreatment significantly inhibited degradation of inhibitory kappa B alpha and modulated ConA-induced nuclear translocation in the liver of nuclear factor kappa B (NF-κB) p65. These results demonstrate that quercetin protects against ConA-mediated hepatitis in mice by attenuating the HMGB1–TLRs–NF-κB signaling pathway.
Literature
1.
go back to reference Thimme, R., S. Wieland, C. Steiger, J. Ghrayeb, K.A. Reimann, R.H. Purcell, et al. 2003. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. Journal of Virology 77: 68–76.PubMedCentralCrossRefPubMed Thimme, R., S. Wieland, C. Steiger, J. Ghrayeb, K.A. Reimann, R.H. Purcell, et al. 2003. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. Journal of Virology 77: 68–76.PubMedCentralCrossRefPubMed
2.
go back to reference Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews Immunology 5: 215–229.CrossRefPubMed Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews Immunology 5: 215–229.CrossRefPubMed
3.
go back to reference Heneghan, M.A., A.D. Yeoman, S. Verma, A.D. Smith, and M.S. Longhi. 2013. Autoimmune hepatitis. Lancet 382: 1433–1444.CrossRefPubMed Heneghan, M.A., A.D. Yeoman, S. Verma, A.D. Smith, and M.S. Longhi. 2013. Autoimmune hepatitis. Lancet 382: 1433–1444.CrossRefPubMed
4.
go back to reference Tiegs, G., J. Hentschel, and A. Wendel. 1992. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. Journal of Clinical Investigation 90: 196–203.PubMedCentralCrossRefPubMed Tiegs, G., J. Hentschel, and A. Wendel. 1992. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. Journal of Clinical Investigation 90: 196–203.PubMedCentralCrossRefPubMed
5.
go back to reference Ajuebor, M.N., J.A. Carey, and M.G. Swain. 2006. CCR5 in T cell-mediated liver diseases: what’s going on. Journal of Immunology 177: 2039–2045.CrossRef Ajuebor, M.N., J.A. Carey, and M.G. Swain. 2006. CCR5 in T cell-mediated liver diseases: what’s going on. Journal of Immunology 177: 2039–2045.CrossRef
6.
go back to reference Kawasuji, A., M. Hasegawa, M. Horikawa, T. Fujita, Y. Matsushita, T. Matsushita, et al. 2006. L-selectin and intercellular adhesion molecule-1 regulate the development of concanavalin A-induced liver injury. Journal of Leukocyte Biology 79: 696–705.CrossRefPubMed Kawasuji, A., M. Hasegawa, M. Horikawa, T. Fujita, Y. Matsushita, T. Matsushita, et al. 2006. L-selectin and intercellular adhesion molecule-1 regulate the development of concanavalin A-induced liver injury. Journal of Leukocyte Biology 79: 696–705.CrossRefPubMed
7.
go back to reference Wang, H., O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.CrossRefPubMed Wang, H., O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.CrossRefPubMed
8.
go back to reference Lotze, M.T., and K.J. Tracey. 2005. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology 5: 331–342.CrossRefPubMed Lotze, M.T., and K.J. Tracey. 2005. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology 5: 331–342.CrossRefPubMed
9.
10.
go back to reference Musumeci, D., G.N. Roviello, and D. Montesarchio. 2014. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacology and Therapeutics 141: 347–357.CrossRefPubMed Musumeci, D., G.N. Roviello, and D. Montesarchio. 2014. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacology and Therapeutics 141: 347–357.CrossRefPubMed
11.
go back to reference Baldwin Jr., A.S. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual Review of Immunology 14: 649–683.CrossRefPubMed Baldwin Jr., A.S. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual Review of Immunology 14: 649–683.CrossRefPubMed
12.
go back to reference Sass, G., S. Heinlein, A. Agli, R. Bang, J. Schumann, and G. Tiegs. 2002. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 19: 115–120.CrossRefPubMed Sass, G., S. Heinlein, A. Agli, R. Bang, J. Schumann, and G. Tiegs. 2002. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 19: 115–120.CrossRefPubMed
13.
go back to reference Tsung, A., J.R. Klune, X. Zhang, G. Jeyabalan, Z. Cao, X. Peng, et al. 2007. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. Journal of Experimental Medicine 204: 2913–2923.PubMedCentralCrossRefPubMed Tsung, A., J.R. Klune, X. Zhang, G. Jeyabalan, Z. Cao, X. Peng, et al. 2007. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. Journal of Experimental Medicine 204: 2913–2923.PubMedCentralCrossRefPubMed
14.
go back to reference Gong, Q., H. Zhang, J.H. Li, L.H. Duan, S. Zhong, X.L. Kong, et al. 2010. High-mobility group box 1 exacerbates concanavalin A-induced hepatic injury in mice. International Journal of Molecular Medicine (Berl) 88: 1289–1298.CrossRef Gong, Q., H. Zhang, J.H. Li, L.H. Duan, S. Zhong, X.L. Kong, et al. 2010. High-mobility group box 1 exacerbates concanavalin A-induced hepatic injury in mice. International Journal of Molecular Medicine (Berl) 88: 1289–1298.CrossRef
15.
go back to reference Takano, K., M. Shinoda, M. Tanabe, T. Miyasho, S. Yamada, S. Ono, et al. 2010. Protective effect of high-mobility group box 1 blockade on acute liver failure in rats. Shock 34: 573–579.CrossRefPubMed Takano, K., M. Shinoda, M. Tanabe, T. Miyasho, S. Yamada, S. Ono, et al. 2010. Protective effect of high-mobility group box 1 blockade on acute liver failure in rats. Shock 34: 573–579.CrossRefPubMed
16.
go back to reference Zhou, R.R., S.S. Zhao, M.X. Zou, P. Zhang, B.X. Zhang, X.H. Dai, et al. 2011. HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterology 11: 21.PubMedCentralCrossRefPubMed Zhou, R.R., S.S. Zhao, M.X. Zou, P. Zhang, B.X. Zhang, X.H. Dai, et al. 2011. HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterology 11: 21.PubMedCentralCrossRefPubMed
17.
go back to reference Tu, C.T., Q.Y. Yao, B.L. Xu, and S.C. Zhang. 2013. Curcumin protects against concanavalin A-induced hepatitis in mice through inhibiting the cytoplasmic translocation and expression of high mobility group box 1. Inflammation 36: 206–215.CrossRefPubMed Tu, C.T., Q.Y. Yao, B.L. Xu, and S.C. Zhang. 2013. Curcumin protects against concanavalin A-induced hepatitis in mice through inhibiting the cytoplasmic translocation and expression of high mobility group box 1. Inflammation 36: 206–215.CrossRefPubMed
18.
go back to reference Schwabe, R.F., E. Seki, and D.A. Brenner. 2006. Toll-like receptor signaling in the liver. Gastroenterology 130: 1886–1900.CrossRefPubMed Schwabe, R.F., E. Seki, and D.A. Brenner. 2006. Toll-like receptor signaling in the liver. Gastroenterology 130: 1886–1900.CrossRefPubMed
19.
go back to reference Ojiro, K., H. Ebinuma, N. Nakamoto, K. Wakabayashi, Y. Mikami, Y. Ono, et al. 2010. MyD88-dependent pathway accelerates the liver damage of Concanavalin A-induced hepatitis. Biochemical and Biophysical Research Communications 399: 744–749.CrossRefPubMed Ojiro, K., H. Ebinuma, N. Nakamoto, K. Wakabayashi, Y. Mikami, Y. Ono, et al. 2010. MyD88-dependent pathway accelerates the liver damage of Concanavalin A-induced hepatitis. Biochemical and Biophysical Research Communications 399: 744–749.CrossRefPubMed
20.
go back to reference Takeuchi, O., and S. Akira. 2010. Pattern recognition receptors and inflammation. Cell 140: 805–820.CrossRefPubMed Takeuchi, O., and S. Akira. 2010. Pattern recognition receptors and inflammation. Cell 140: 805–820.CrossRefPubMed
21.
go back to reference Xu, J., X. Zhang, M. Monestier, N.L. Esmon, and C.T. Esmon. 2011. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. Journal of Immunology 187: 2626–2631.CrossRef Xu, J., X. Zhang, M. Monestier, N.L. Esmon, and C.T. Esmon. 2011. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. Journal of Immunology 187: 2626–2631.CrossRef
22.
go back to reference Tu, C.T., B. Han, Q.Y. Yao, Y.A. Zhang, H.C. Liu, and S.C. Zhang. 2012. Curcumin attenuates Concanavalin A-induced liver injury in mice by inhibition of toll-like receptor (TLR) 2, TLR4 and TLR9 expression. International Immunopharmacology 12: 151–157.CrossRefPubMed Tu, C.T., B. Han, Q.Y. Yao, Y.A. Zhang, H.C. Liu, and S.C. Zhang. 2012. Curcumin attenuates Concanavalin A-induced liver injury in mice by inhibition of toll-like receptor (TLR) 2, TLR4 and TLR9 expression. International Immunopharmacology 12: 151–157.CrossRefPubMed
23.
go back to reference Formica, J.V., and W. Regelson. 1995. Review of the biology of quercetin and related bioflavonoids. Food and Chemical Toxicology 33: 1061–1080.CrossRefPubMed Formica, J.V., and W. Regelson. 1995. Review of the biology of quercetin and related bioflavonoids. Food and Chemical Toxicology 33: 1061–1080.CrossRefPubMed
24.
go back to reference Del, P.A., A. Scalera, M.D. Iadevaia, A. Miranda, C. Zulli, L. Gaeta, et al. 2012. Herbal products: benefits, limits, and applications in chronic liver disease. Evidence-based Complementary and Alternative Medicine 2012: 837939. Del, P.A., A. Scalera, M.D. Iadevaia, A. Miranda, C. Zulli, L. Gaeta, et al. 2012. Herbal products: benefits, limits, and applications in chronic liver disease. Evidence-based Complementary and Alternative Medicine 2012: 837939.
25.
go back to reference Bhaskar, S., V. Shalini, and A. Helen. 2011. Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF-kappaB signaling pathway. Immunobiology 216: 367–373.CrossRefPubMed Bhaskar, S., V. Shalini, and A. Helen. 2011. Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF-kappaB signaling pathway. Immunobiology 216: 367–373.CrossRefPubMed
26.
go back to reference Marcolin, E., B. San-Miguel, D. Vallejo, J. Tieppo, N. Marroni, J. Gonzalez-Gallego, et al. 2012. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. Journal of Nutrition 142: 1821–1828.CrossRefPubMed Marcolin, E., B. San-Miguel, D. Vallejo, J. Tieppo, N. Marroni, J. Gonzalez-Gallego, et al. 2012. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. Journal of Nutrition 142: 1821–1828.CrossRefPubMed
27.
go back to reference Byun, E.B., M.S. Yang, H.G. Choi, N.Y. Sung, D.S. Song, S.J. Sin, et al. 2013. Quercetin negatively regulates TLR4 signaling induced by lipopolysaccharide through Tollip expression. Biochemical and Biophysical Research Communications 431: 698–705.CrossRefPubMed Byun, E.B., M.S. Yang, H.G. Choi, N.Y. Sung, D.S. Song, S.J. Sin, et al. 2013. Quercetin negatively regulates TLR4 signaling induced by lipopolysaccharide through Tollip expression. Biochemical and Biophysical Research Communications 431: 698–705.CrossRefPubMed
28.
go back to reference Tang, D., R. Kang, W. Xiao, H. Zhang, M.T. Lotze, H. Wang, et al. 2009. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. American Journal of Respiratory Cell and Molecular Biology 41: 651–660.PubMedCentralCrossRefPubMed Tang, D., R. Kang, W. Xiao, H. Zhang, M.T. Lotze, H. Wang, et al. 2009. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. American Journal of Respiratory Cell and Molecular Biology 41: 651–660.PubMedCentralCrossRefPubMed
29.
go back to reference Su, J.F., C.J. Guo, J.Y. Wei, J.J. Yang, Y.G. Jiang, and Y.F. Li. 2003. Protection against hepatic ischemia-reperfusion injury in rats by oral pretreatment with quercetin. Biomedical and Environmental Sciences 16: 1–8.PubMed Su, J.F., C.J. Guo, J.Y. Wei, J.J. Yang, Y.G. Jiang, and Y.F. Li. 2003. Protection against hepatic ischemia-reperfusion injury in rats by oral pretreatment with quercetin. Biomedical and Environmental Sciences 16: 1–8.PubMed
30.
go back to reference de David, C., G. Rodrigues, S. Bona, L. Meurer, J. Gonzalez-Gallego, M.J. Tunon, et al. 2011. Role of quercetin in preventing thioacetamide-induced liver injury in rats. Toxicologic Pathology 39: 949–957.CrossRefPubMed de David, C., G. Rodrigues, S. Bona, L. Meurer, J. Gonzalez-Gallego, M.J. Tunon, et al. 2011. Role of quercetin in preventing thioacetamide-induced liver injury in rats. Toxicologic Pathology 39: 949–957.CrossRefPubMed
31.
go back to reference Domitrovic, R., H. Jakovac, M.V. Vasiljev, S. Vladimir-Knezevic, O. Cvijanovic, Z. Tadic, et al. 2012. Differential hepatoprotective mechanisms of rutin and quercetin in CCl (4)-intoxicated BALB/cN mice. Acta Pharmacologica Sinica 33: 1260–1270.PubMedCentralCrossRefPubMed Domitrovic, R., H. Jakovac, M.V. Vasiljev, S. Vladimir-Knezevic, O. Cvijanovic, Z. Tadic, et al. 2012. Differential hepatoprotective mechanisms of rutin and quercetin in CCl (4)-intoxicated BALB/cN mice. Acta Pharmacologica Sinica 33: 1260–1270.PubMedCentralCrossRefPubMed
32.
go back to reference Yumoto, E., T. Higashi, K. Nouso, H. Nakatsukasa, K. Fujiwara, T. Hanafusa, et al. 2002. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. Journal of Gastroenterology and Hepatology 17: 285–294.CrossRefPubMed Yumoto, E., T. Higashi, K. Nouso, H. Nakatsukasa, K. Fujiwara, T. Hanafusa, et al. 2002. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. Journal of Gastroenterology and Hepatology 17: 285–294.CrossRefPubMed
33.
go back to reference Castellano-Higuera, A., E. Gonzalez-Reimers, M.R. Aleman-Valls, P. Abreu-Gonzalez, F. Santolaria-Fernandez, M.J. De La Vega-Prieto, et al. 2008. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol and Alcoholism 43: 137–142.CrossRefPubMed Castellano-Higuera, A., E. Gonzalez-Reimers, M.R. Aleman-Valls, P. Abreu-Gonzalez, F. Santolaria-Fernandez, M.J. De La Vega-Prieto, et al. 2008. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol and Alcoholism 43: 137–142.CrossRefPubMed
34.
go back to reference Zou, Z., B. Li, D. Xu, Z. Zhang, J.M. Zhao, G. Zhou, et al. 2009. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. Journal of Clinical Gastroenterology 43: 182–190.CrossRefPubMed Zou, Z., B. Li, D. Xu, Z. Zhang, J.M. Zhao, G. Zhou, et al. 2009. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. Journal of Clinical Gastroenterology 43: 182–190.CrossRefPubMed
35.
go back to reference Park, J.S., D. Svetkauskaite, Q. He, J.Y. Kim, D. Strassheim, A. Ishizaka, et al. 2004. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry 279: 7370–7377.CrossRefPubMed Park, J.S., D. Svetkauskaite, Q. He, J.Y. Kim, D. Strassheim, A. Ishizaka, et al. 2004. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry 279: 7370–7377.CrossRefPubMed
36.
go back to reference Chen, Y., and R. Sun. 2011. Toll-like receptors in acute liver injury and regeneration. International Immunopharmacology 11: 1433–1441.CrossRefPubMed Chen, Y., and R. Sun. 2011. Toll-like receptors in acute liver injury and regeneration. International Immunopharmacology 11: 1433–1441.CrossRefPubMed
37.
go back to reference Uesugi, T., M. Froh, G.E. Arteel, B.U. Bradford, and R.G. Thurman. 2001. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 34: 101–108.CrossRefPubMed Uesugi, T., M. Froh, G.E. Arteel, B.U. Bradford, and R.G. Thurman. 2001. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 34: 101–108.CrossRefPubMed
38.
go back to reference Xiao, X., P. Zhao, D. Rodriguez-Pinto, D. Qi, O. Henegariu, L. Alexopoulou, et al. 2009. Inflammatory regulation by TLR3 in acute hepatitis. Journal of Immunology 183: 3712–3719.CrossRef Xiao, X., P. Zhao, D. Rodriguez-Pinto, D. Qi, O. Henegariu, L. Alexopoulou, et al. 2009. Inflammatory regulation by TLR3 in acute hepatitis. Journal of Immunology 183: 3712–3719.CrossRef
39.
go back to reference Luedde, T., and R.F. Schwabe. 2011. NF-kappaB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology 8: 108–118.CrossRef Luedde, T., and R.F. Schwabe. 2011. NF-kappaB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology 8: 108–118.CrossRef
40.
go back to reference Schumann, J., J. Prockl, A.K. Kiemer, A.M. Vollmar, R. Bang, and G. Tiegs. 2003. Silibinin protects mice from T cell-dependent liver injury. Journal of Hepatology 39: 333–340.CrossRefPubMed Schumann, J., J. Prockl, A.K. Kiemer, A.M. Vollmar, R. Bang, and G. Tiegs. 2003. Silibinin protects mice from T cell-dependent liver injury. Journal of Hepatology 39: 333–340.CrossRefPubMed
41.
go back to reference Hoffmann, F., G. Sass, J. Zillies, S. Zahler, G. Tiegs, A. Hartkorn, et al. 2009. A novel technique for selective NF-kappaB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia-reperfusion. Gut 58: 1670–1678.CrossRefPubMed Hoffmann, F., G. Sass, J. Zillies, S. Zahler, G. Tiegs, A. Hartkorn, et al. 2009. A novel technique for selective NF-kappaB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia-reperfusion. Gut 58: 1670–1678.CrossRefPubMed
42.
go back to reference Comalada, M., D. Camuesco, S. Sierra, I. Ballester, J. Xaus, J. Galvez, et al. 2005. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. European Journal of Immunology 35: 584–592.CrossRefPubMed Comalada, M., D. Camuesco, S. Sierra, I. Ballester, J. Xaus, J. Galvez, et al. 2005. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. European Journal of Immunology 35: 584–592.CrossRefPubMed
43.
go back to reference Bharrhan, S., K. Chopra, S.K. Arora, J.S. Toor, and P. Rishi. 2012. Down-regulation of NF-kappaB signalling by polyphenolic compounds prevents endotoxin-induced liver injury in a rat model. Innate Immunity 18: 70–79.CrossRefPubMed Bharrhan, S., K. Chopra, S.K. Arora, J.S. Toor, and P. Rishi. 2012. Down-regulation of NF-kappaB signalling by polyphenolic compounds prevents endotoxin-induced liver injury in a rat model. Innate Immunity 18: 70–79.CrossRefPubMed
44.
go back to reference Liu, H., C.R. Lo, and M.J. Czaja. 2002. NF-kappaB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 35: 772–778.CrossRefPubMed Liu, H., C.R. Lo, and M.J. Czaja. 2002. NF-kappaB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 35: 772–778.CrossRefPubMed
Metadata
Title
Quercetin Protects Mice from ConA-Induced Hepatitis by Inhibiting HMGB1-TLR Expression and Down-Regulating the Nuclear Factor Kappa B Pathway
Authors
Xi Li
Hong-chun Liu
Qun-yan Yao
Bei-li Xu
Shun-cai Zhang
Chuan-tao Tu
Publication date
01-02-2016
Publisher
Springer US
Published in
Inflammation / Issue 1/2016
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-015-0227-9

Other articles of this Issue 1/2016

Inflammation 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine